FDA Turns Off Otsuka’s Abilify Dimmer Switch Graphic
This article was originally published in The Pink Sheet Daily
Executive Summary
As lights go out on the franchise, FDA says pharmacology aid misleadingly suggests Abilify offers advantages over other treatments.
You may also be interested in...
Efficacy Overstatements In Evofem’s Phexxi Brochure, Otsuka’s Rexulti TV Ad Draw Untitled Letters
US FDA releases two letters on the same day citing two different kinds of advisements for two different kinds of products, but both with a classic problem: overstatement of efficacy. And while sending multiple letters at once can be seen as bid to draw attention to its enforcement action, the move also underscores just how few letters the agency has been sending lately.
Do Ads Noting A Drug’s ‘Targeted’ Mechanism Of Action Impact Perceptions Of the Product?
US FDA will study how presentations of a fictitious cancer drug’s targeted mechanism of action affect consumer and provider interest in the drug and their understanding of its benefits and risks. Another study will assess how consumers and primary care physicians interpret Rx drug names.
DTC Safety Messages Could Vary By Platform As FDA Considers Screen Size
Both tablets and huge TVs have proliferated since the last research of the impact of superimposed text.